Latest News & Updates

Breaking News

  • 2 hours ago

  • Simantini Singh Deo

Roche’s Elecsys® NfL Test Wins CE Mark For Detecting Neuroinflammation In Relapsing-Remitting Multiple Sclerosis
Breaking News
Nxera Pharma Secures US$22.5 Million As Partner Neurocrine Launches Phase 2 Trial For Schizophrenia Drug NBI-1117570

Simantini Singh Deo

Other trending news you may like to read

Roche’s Elecsys® NfL Test Wins CE Mark For Detecting Neuroinflammation In Relapsing-Remitting Multiple Sclerosis

Roche secures CE mark approval for Elecsys NfL test to detect neuroinflammation in relapsing-remitting multiple sclerosis, enabling blood-based monitoring of disease activity.

Simantini Singh Deo

Pharma Now

Nxera Pharma Secures US$22.5 Million As Partner Neurocrine Launches Phase 2 Trial For Schizophrenia Drug NBI-1117570

Nxera Pharma Co., Ltd. secures US$22.5M milestone as Neurocrine begins Phase 2 trial of NBI-1117570 to treat schizophrenia, evaluating safety and efficacy in adults.

Simantini Singh Deo

Pharma Now

European Commission Approves Dupixent For Young Children With Chronic Spontaneous Urticaria, Expanding EU Use

Regeneron Pharmaceuticals, Inc. gains European Commission approval for Dupixent (dupilumab) to treat chronic spontaneous urticaria in children aged 2–11 years.

Simantini Singh Deo

Pharma Now

Thermo Fisher Scientific Inc. And Precision Health Research, Singapore (PRECISE) Team Up To Advance PRECISE-SG100K, One Of Asia’s Largest Population-Scale Proteomics Studies

Thermo Fisher Scientific Inc. collaborates on PRECISE-SG100K proteomics study to advance biomarker discovery and improve disease understanding using population-scale protein data.

Simantini Singh Deo

Pharma Now